Presentation is loading. Please wait.

Presentation is loading. Please wait.

Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.

Similar presentations


Presentation on theme: "Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK."— Presentation transcript:

1 Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK

2 HPS: Eligibility criteria Increased risk of CHD death due to prior disease: Myocardial infarction or other CHD; Occlusive disease of non-coronary arteries; or Diabetes mellitus or treated hypertension Age 40-80 years Total cholesterol  3.5 mmol/l (  135mg/dl) Statin or vitamins not considered clearly indicated or contraindicated by patient’s own doctors

3 Cost-effectiveness analysis of allocation to 40mg daily simvastatin Based on within trial period only (mean 5 years) Costs for UK National Health Service (2001) Cost-effectiveness analyses undertaken: –per major vascular event* avoided –per vascular death avoided –overall and in subgroups at differing absolute risk *first or subsequent heart attack, stroke or revascularisation following randomisation

4 Major vascular events (MVE) and vascular deaths per 1000 patients Simvastatin allocated Placebo allocated Avoided per 1000 (SE) All MVE27035989 (10) Vascular death 76 9115 (4)

5 HPS: Methods of calculating costs Costs included Study simvastatin (40mg daily at £1/day) and any non-study statin Hospitalisations for all major and other vascular events Costs excluded Non-statin drugs Hospitalisations for non-vascular events (no significant differences between groups) Primary and social care costs (no data available in HPS )

6 Mean costs per patient for statin use and hospitalisation for any vascular event Cost category Simvastatin (n = 10,269) Placebo (n = 10,267) Difference (SE) Statin use £1,712 £215 £1,497 (8) Vascular events £1,819£2,319-£500 (78) Total£3,530£2,534£996 (79)

7 Cost per MVE avoided: £11,000 (£8-16,000) Cost per vascular death avoided: £66,000 (£42-135,000) Overall cost-effectiveness within trial (95% CI)

8 Assessing subgroup effects reliably Analyses in different subgroups indicate: –Similar relative reduction in vascular events –Similar relative reduction in costs of vascular events –Similar absolute difference in statin treatment cost Hence, cost-effectiveness for subgroups estimated by applying overall treatment effects to placebo event rates and costs observed in each subgroup

9 Cox model on baseline characteristics used to create 5 multivariate risk groups Risk Group Number5-yr risk MVE 5-yr risk MCE 5-yr risk vascular death 1234512345 4107 4108 12% 18% 23% 28% 42% 4% 7% 10% 13% 22% 3% 5% 7% 10% 18%

10 Similar relative reduction in first MVE by prior disease and age SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) Prior disease Any CHD21.8%27.5% No prior CHD CVD18.7%23.6% PVD24.7%30.5% Diabetes13.8%18.6% Age (years) <6516.9%22.1% ≥65 <7020.9%27.2% ≥7023.6%28.7% ALL PATIENTS19.8%25.2% 24% SE 3 reduction (2P<0.00001) 0.40.60.81.01.21.4

11 Similar relative reduction in first MVE by LDL & HDL SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) LDL Cholesterol (mmol/l) <3.017.6%22.2% ≥3.0 <3.519.0%25.7% ≥3.522.0%27.2% HDL Cholesterol (mmol/l) <0.922.6%29.9% ≥0.9 <1.120.0%25.1% ≥1.117.0%20.9% ALL PATIENTS19.8%25.2% 24% SE 3 reduction (2P<0.00001) 0.40.60.81.01.21.4

12 Similar relative reduction in first MVE by risk group SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Risk group (10269)(10267) 1 (low risk)8.3%11.8% 213.9%18.2% 318.4%24.9% 424.5%29.6% 5 (high risk)33.8%41.4% ANY OF ABOVE19.8%25.2% 24% SE 3 reduction (2P<0.00001) 0.40.60.81.01.21.4

13 Similar relative reduction in costs (£) of all vascular events by prior disease and age STATINPLACEBOBaseline feature Prior disease Any CHD21582675 No prior CHD CVD12811641 PVD18662563 Diabetes10761445  2 3 =0.8 Age < 6515722066 65 - 7019582369 > 7021152710  2 2 =0.8 ALL PATIENTS181923190.78 (0.73-0.84) 0.40.60.81.01.21.4

14 Similar relative reduction in costs (£) of all vascular events by risk group STATINPLACEBORisk group 1 (low risk)7841219 213641746 317732120 421682610 5 (high risk)30003903  2 4 =4.0 ALL PATIENTS181923190.78 (0.73-0.84) 0.40.60.81.01.21.4

15 Similar absolute difference in statin costs by risk group Statin costs (£) Difference£1555£1536£1534£1485£1371 (SE)(16)(17) (19) S P S P S P S P S P Risk group 1 2 3 4 5 0 500 1000 1500 2000

16 Similar absolute difference in statin costs by disease and age Statin costs (£) Difference£1494£1503£1494£1514£1488 (SE)(10)(12)(11)(16)(14) S P S P S P S P S P Prior disease No CHD Any CHD < 65 ≥ 65 < 70 ≥ 70 Age (years) 0 500 1000 1500 2000

17 Vascular event cost-savings by risk group 100% 50% % Current simvastatin price 25% 12% 5-yr risk MVE 42% 5-yr risk MVE

18 50% Vascular event cost-savings by risk group 100% % Current simvastatin price 25% 12% 5-yr risk MVE 42% 5-yr risk MVE

19 50% 25% Vascular event cost-savings by risk group 100% % Current simvastatin price 12% 5-yr risk MVE 42% 5-yr risk MVE

20 Cost per MVE avoided by risk group Overall: £11,000 12% 5-yr risk MVE 42% 5-yr risk MVE

21 Cost per vascular death avoided by risk group Overall: £66,000 12% 5-yr risk MVE 42% 5-yr risk MVE

22 On-going health economic analyses Extrapolation to effects beyond trial period Assessment of cost per QALY Adapt analyses to other countries

23 CONCLUSIONS: Economic evaluation of HPS Simvastatin allocation reduced vascular hospitalisation costs by 22% regardless of patient characteristics Cost-effectiveness is chiefly determined by an individual’s overall risk of vascular events (rather than by single risk factors, such as LDL) Statin treatment is cost-effective for a wide range of high-risk individuals (and will become increasingly so as statin prices fall)


Download ppt "Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK."

Similar presentations


Ads by Google